Press Release: Alpharma Signs License Pact for Tris Pharma Drug Delivery Technology

Alpharma Signs License Pact for Tris Pharma Drug Delivery Technology FORT LEE, N.J., March 29 -- Alpharma Inc., a leading global specialty pharmaceutical company, announced it has entered into an exclusive licensing agreement with Tris Pharma, Inc. ("Tris"), a privately owned specialty pharmaceutical company engaged in the research and development of drug delivery technologies. Under the terms of the agreement, Alpharma will gain access to Tris' LiquiXR(TM) technology, a novel and proprietary drug delivery platform for sustained release products in liquid form. The company plans to use this technology to develop an oral liquid product complementary to the company's KADIAN® solid dose product line. This planned addition to the KADIAN® product line is targeted to address the significant unmet need for liquid dose sustained release opioids, especially in the long-term and institutional care markets. In addition, Alpharma is collaborating with Tris to leverage its technology to further improve the attributes of KADIAN® product line. This development program will be complementary to Alpharma's abuse deterrent platform which utilizes the antagonist, naltrexone. Both companies will collaborate on the development of these pain management products, and upon approval, Tris will be responsible for manufacturing, and Alpharma will commercialize the products. "We are extremely pleased to be partnering with Tris to expand our late stage development pipeline to provide innovative solutions in pain management for physicians and patients," commented Dean Mitchell, President and Chief Executive Officer of Alpharma, "When combined with our current Kadian® NT program, the products contemplated in this development agreement will offer additional treatment options for chronic moderate to severe pain." Ketan Mehta, President and Chief Executive Officer of Tris Pharma noted, "We have been impressed with Alpharma's deep understanding of the treatment modalities associated with pain. Our team is looking forward to combining Tris' strong expertise in development with Alpharma's clinical, regulatory and marketing know-how." Under the terms of the agreement, the company expects approximately $15 million in expenses related to milestone payments to Tris and other clinical development expenses tied primarily to key development and intellectual property events. Approximately half of these costs could be incurred in 2007. The agreement calls for royalty payments on net sales and certain additional payments to be made based on sales performance. If the products meet certain pre-determined clinical targets, regulatory submissions could be filed in 2008. About Alpharma Inc. Alpharma Inc. (NYSE: ALO - News) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded pharmaceuticals franchise in the chronic pain market with its morphine-based extended release KADIAN® product. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock About Tris Pharma, Inc. Tris Pharma, Inc. is a privately held, product-driven drug delivery technology company. Tris specializes in controlled release for liquid, solid, and ODT dosage forms; abuse deterrent technologies; and enhancement of bioavailability for poorly soluble drugs. Through its pharma partners, Tris has over 30 products in development, submission or market. Tris' R&D and manufacturing facilities are located in South Brunswick, New Jersey. Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The 2006 outlook assumes no material adverse event contemplated by the risk factors described in the Company's SEC filings. Information on other significant potential risks and uncertainties not discussed herein may be found in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2006.

Suggested Articles

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"